The most common alterations include exon 19 deletions (45% of all EGFR-activating mutations) and the L858R point mutation in exon 21 (40–45%), which together comprise most EGFR-driven NSCLC cases [6]. Here, EGFR is linked to non-small cell lung carcinoma.